The multiple myeloma market is becoming increasingly crowded. In 2015, several new, high-priced therapies have been approved for in the treatment of multiple myeloma, making this lucrative market more dynamic and competitive. Although these new therapies have significantly improved the outcomes for multiple myeloma, most patients relapse and ultimately die of their disease. Owing to the high level of unmet need in multiple myeloma, significant clinical and commercial opportunity remains for therapies that can provide greater survival benefits compared with current standards of care. 


Related Reports

Multiple Myeloma - Landscape & Forecast - Disease Landscape & Forecast

The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and long treatment durations. The availability of premium-priced branded agents prescribed...

View Details

Multiple Myeloma - Epidemiology - Emerging Markets

DRG Epidemiology’s coverage of multiple myeloma comprises epidemiological estimates of key patient populations in 45 countries w...

View Details

Multiple Myeloma - Epidemiology - Mature Markets

DRG Epidemiology's coverage of multiple myeloma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We re...

View Details

Multiple Myeloma - Epidemiology - Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key multiple myeloma patient pop...

View Details